Monarche: Adjuvant Abemaciclib In Hr+ Breast Cancer

monarchE: adjuvant abemaciclib in HR+ breast cancer

monarchE: abemaciclib and adjuvant endocrine therapy for high-risk HR+ early breast cancer

monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC

MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancer

MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC

Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer

4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC

Age-stratified findings from the monarchE trial of abemaciclib in breast cancer

MonarchE results: Abemaciclib plus endocrine therapy in high-risk early breast cancer

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data

Adjuvant Abemaciclib/Ribociclib #monarchE/NATALEE #Best Treatment for Breast cancer #CDK 4/6 -Cure

Cancer education made simple # Chandrakanth MV

Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer

Erika Hamilton, MD, considers the significance of the monarchE study & the use of abemaciclib

monarchE: patient-reported outcomes

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study

European Society for Medical Oncology (ESMO)

Adjuvant CDK4/6 inhibition in early-stage HR-positive breast cancer | Ruth O'Regan

Medicine Matters oncology

5-year monarchE results: abemaciclib + ET in high-risk EBC

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancer

European Society for Medical Oncology (ESMO)

NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer

monarchE and PALLAS: A tale of two CDK4/6 inhibitors | George Sledge Jr

Medicine Matters oncology